A Semaine Health evidence guide. Every claim is sourced; studies linked throughout.
The short answer
Cranberry's reputation is mixed for one under-discussed reason: absorption, not cranberry. The active compounds — proanthocyanidins, or PACs — have well-studied effects against the bacteria behind UTIs, but in standard cranberry juice and most pills, those compounds largely don't survive digestion intact, so they never reach the urinary tract at a meaningful dose. When you fix the delivery, the compounds can be measured arriving in human urine and acting there. That single distinction explains most of the confusing research — and it's why "cranberry didn't work for me" is usually a story about the form, not the fruit.
Why the research on cranberry looks so contradictory
If you've seen headlines saying cranberry works and others saying it doesn't, you're reading real science — it genuinely disagrees with itself. A 2017 systematic review and meta-analysis of 7 randomized trials (n=1,498) found cranberry reduced the risk of UTI recurrence by 26% in otherwise healthy women (Fu et al., 2017, J Nutr). But a large 2016 trial in nursing-home women found no benefit (Juthani-Mehta et al., 2016, JAMA), and a 2021 trial of high-dose cranberry PACs missed its primary endpoint (Babar et al., 2021, BMC Urol).
So is cranberry useless? No. Look closer and a pattern emerges: the studies disagree largely on dose and delivery — how much active PAC actually reached the urinary tract. Which points at the real variable.
The active compound — and why it usually doesn't arrive
The molecules that matter in cranberry are proanthocyanidins (PACs), specifically the A-type linkages studied for interfering with bacterial adhesion. The problem is that standard cranberry — juice, most extracts, the bottle next to the register — delivers PACs that are poorly absorbed. If the active compounds don't survive digestion and reach the urine, it doesn't matter how good the mechanism looks in a dish.
That's why dose and form keep showing up as the deciding factor. In a randomized study, anti-adhesion activity in human urine was dose-dependent, with protection lasting up to 24 hours at 72 mg of PACs per day (Howell et al., 2010, BMC Infect Dis). Under-deliver the active compound and you get an under-whelming result — which is exactly what a lot of cranberry research did.
What "actually arriving" looks like — measured
This is where it gets concrete, because it's been measured. A phytosome binds plant compounds to phospholipids to improve how much survives digestion. In published research, after people ingested a standardized cranberry phytosome (Anthocran®), 42 cranberry-derived compounds and metabolites were identified in human urine — including valerolactones never previously described — and urine fractions collected 12 hours after dosing significantly reduced biofilm formation by a biofilm-forming organism (Candida albicans) in lab testing (p<0.05) (Baron et al., 2019, Biochem Pharmacol). A follow-up confirmed two of those urinary metabolites drive the anti-biofilm effect (Ottaviano et al., 2021, Microorganisms).
That's the bridge most of the category can't build: not "cranberry is associated with urinary health," but the compounds were detected at the site, and were active once there.
Two mechanisms, measured separately
It's worth being precise, because the evidence supports two distinct things:
- Reduced adhesion against uropathogenic E. coli — the bacterium behind most UTIs. Cranberry PACs and their urinary metabolites lower E. coli's ability to grip bladder cells, dose-dependently (Howell et al., 2010; Howell et al., 2015, Nat Prod Commun; de Llano et al., 2015, Int J Mol Sci).
- Inhibited biofilm formation — demonstrated in a Candida albicans model, the standard way to test anti-biofilm activity (Baron et al., 2019; Rane et al., 2013, J Antimicrob Chemother).
One angle reduces the grip; the other works against the protective structure bacteria build. We're careful not to overstate this: the biofilm data is a laboratory model, and the E. coli data is about adhesion — not a claim that any supplement dissolves an established infection on the human bladder.
The clinical signal in the right delivery form
When the delivery problem is solved, the clinical picture improves. In a 2024 double-blind randomized controlled trial, daily supplementation with 120 mg of standardized cranberry phytosome significantly modulated urinary tract episodes versus placebo — in diabetic postmenopausal women taking SGLT-2 inhibitors, a group at substantially elevated urinary tract risk (Rondanelli et al., 2024, Nutrients). The result is more compelling because of that high-risk population, not despite it. A separate registry study found a protective effect in post-catheterization patients (Cotellese et al., 2021, J Diet Suppl).
So — does cranberry work?
The honest, evidence-led answer: the right cranberry compounds, in a form that actually absorbs, reduce bacterial adhesion and inhibit biofilm formation, and standardized cranberry phytosome has shown benefit in clinical trials — while standard, poorly-absorbed cranberry produces inconsistent results. Cranberry is supportive, daily, preventive care for a healthy urinary environment, not a treatment for an active infection. If you've tried cranberry and felt nothing, the most likely explanation is that the active compounds never arrived.
How Semaine applies this
Semaine's Urinary Tract Cleanse & Protect uses Anthocran® Phytosome® — the exact bioavailability-enhanced cranberry form used in the published research above, not a generic cranberry pill sold next to studies it wasn't part of — plus standardized hibiscus. It supports a healthy urinary environment and daily urinary tract health.
Frequently asked questions
Why doesn't cranberry juice work for UTIs?
The issue is usually absorption, not cranberry. The active proanthocyanidins (PACs) in standard juice and extracts largely don't survive digestion, so they don't reach the urinary tract at a meaningful concentration — which is why cranberry research is so inconsistent (Howell et al., 2010).
What is cranberry phytosome?
A delivery form that binds cranberry compounds to phospholipids to improve how much survives digestion. After ingesting cranberry phytosome, researchers identified the compounds in human urine and showed they were active there (Baron et al., 2019).
How much PAC does cranberry need to be effective?
Anti-adhesion activity in urine was dose-dependent, with protection up to 24 hours at 72 mg of PACs per day in one randomized study (Howell et al., 2010). Dose and delivery are why studies disagree.
Is there clinical evidence for cranberry phytosome specifically?
Yes — a 2024 randomized controlled trial found 120 mg/day of standardized cranberry phytosome significantly modulated urinary tract episodes vs placebo in postmenopausal women at elevated risk (Rondanelli et al., 2024).
Does cranberry treat an active UTI?
No. The evidence is about supporting a healthy urinary environment and reducing bacterial adhesion as daily, preventive care — not treating an active infection. See a clinician for symptoms of an active UTI.
Educational content; not medical advice. Sources are peer-reviewed and indexed on PubMed.